Reporting owner · CIK 0001241033

Rioux Patrice

Visual SEC Form 4 history across 1 companies, 6 transactions and 4 filings.

ACMOMonopar Therapeutics
Open-market mix
Filings4Form 4 records
Buying$00 purchases
Selling$111.31 sales
Net value−$111.3Buys minus sells
Companies13 securities
Most recentAug 26, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-5Jan 24Jan 25Jan 261Aug 26

Net value flow

Buys minus sells

Jan 24
$0
Jan 25
$0
Jan 26
$0
Aug 26
−$111.3

Transaction texture

Ownership and ticket size

Average P/S size$111.3
Median P/S size$111.3
Direct6
Indirect0
Aug 26, 2026exercise

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Monopar Therapeutics on Aug 26, 2026 valued at $111.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Associated companies

Visual map of known reporting history

Rioux Patrice Insider Activity FAQ

SEC Form 4 context

Who is Rioux Patrice?

Rioux Patrice is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001241033.

Which companies has Rioux Patrice reported transactions for?

Monopar Therapeutics

When was Rioux Patrice's latest insider buy?

No open-market insider purchase is available for this period.

When was Rioux Patrice's latest insider sale?

sale at Monopar Therapeutics on Aug 26, 2026 valued at $111.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.